NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 47.94% | -115.64% | 8.40% | 13.89% | 17.67% |
Total Depreciation and Amortization | 91.64% | -29.41% | -14.00% | 1.53% | 94.27% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -55.21% | 118.26% | -8.10% | -18.35% | 618.49% |
Change in Net Operating Assets | -697.01% | -69.54% | 347.94% | 112.62% | -220.81% |
Cash from Operations | -933.47% | -133.26% | 703.26% | 94.55% | -116.88% |
Capital Expenditure | -18.66% | 16.30% | 6.67% | 2.87% | -72.76% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 131.19% | -163.56% | 105.75% | -240.70% | 144.97% |
Cash from Investing | 70.86% | -317.90% | 102.72% | -252.08% | 149.97% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 95.42% | 2,585.00% | -96.98% | 1,453.05% | -88.85% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 95.42% | 2,585.00% | -99.89% | 40,893.90% | -88.85% |
Foreign Exchange rate Adjustments | 277.34% | -247.13% | 212.99% | -37.50% | -128.00% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -58.68% | -211.32% | 107.18% | -234.51% | 149.62% |